Announcements Trials
Browse Landscape

Status

Recruiting 5Terminated 1Suspended 1Not yet recruiting 1Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatoses 1Neurofibroma, Plexiform 1

Interventions

balstilimab 2zipalertinib 1tisagenlecleucel 1ribociclib 1nirogacestat 1mirdametinib 1mifamurtide 1lifileucel 1leronlimab 1fluorodopa F 18 1dodecyl maltoside 1carbon-11 methionine 1brexucabtagene autoleucel 1Sunitinib 1Methionine 1Alpelisib 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × mirdametinib × 90 days × Clear all
NCT05028166 2026-05-08

Individual Patient Compassionate Use of Mirdametinib

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Available
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡